Oblique Therapeutics AB (Gothenburg, Sweden) holds a novel antibody platform that allows the identification of new therapeutic antibodies towards targets that cannot be addressed with traditional antibody technology.
By focusing on previously undruggable targets Oblique Therapeutics pursues novel antibody therapies within pain and aggressive-metastatic cancer. The platform technology, Abiprot™, is based on a molecular reporter system and proteomics that yield detailed sequence and structure information for epitope identification and development. The platform has yielded a diverse pipeline of projects in pre-clinical development, including four programs that are being developed with partners. The most progressed projects are targeting KRAS and TRPV1.
For more information, please contact:
Phone +45 2481 6967